Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Patricia Haney"'
Autor:
Anne-Marie Martin, Jeffrey Legos, Vicki Goodman, Jennifer Carver, Anne O'Hagan, Patricia Haney, Patrick Hwu, Axel Hauschild, Richard Kefford, Keith Flaherty, Dirk Schadendorf, Georgina V. Long, Michelle Casey, Jolly Mazumdar, Robert Gagnon, Ademi Santiago-Walker
Purpose: Tumor-derived circulating cell–free DNA (cfDNA) is a potential alternative source from which to derive tumor mutation status. cfDNA data from four clinical studies of the BRAF inhibitor (BRAFi) dabrafenib or the MEK inhibitor (MEKi) tramet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b4d3d38da62573352abaa7748422d3c
https://doi.org/10.1158/1078-0432.c.6524792.v1
https://doi.org/10.1158/1078-0432.c.6524792.v1
Autor:
Anne-Marie Martin, Jeffrey Legos, Vicki Goodman, Jennifer Carver, Anne O'Hagan, Patricia Haney, Patrick Hwu, Axel Hauschild, Richard Kefford, Keith Flaherty, Dirk Schadendorf, Georgina V. Long, Michelle Casey, Jolly Mazumdar, Robert Gagnon, Ademi Santiago-Walker
Supplementary Figure S1. Distribution of BRAF V600E cfDNA mutation fraction across study samples; Supplementary Figure S2. cfDNA-ND patients exhibited higher response rates to dabrafenib and trametinib compared with cfDNA V600E/K patients; Supplement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f3ce7b899723d4e09fb698884ab6a5e
https://doi.org/10.1158/1078-0432.22461464
https://doi.org/10.1158/1078-0432.22461464
Autor:
Anne-Marie Martin, Jeffrey Legos, Vicki Goodman, Jennifer Carver, Anne O'Hagan, Patricia Haney, Patrick Hwu, Axel Hauschild, Richard Kefford, Keith Flaherty, Dirk Schadendorf, Georgina V. Long, Michelle Casey, Jolly Mazumdar, Robert Gagnon, Ademi Santiago-Walker
Supplementary Figure S1. Distribution of BRAF V600E cfDNA mutation fraction across study samples; Supplementary Figure S2. cfDNA-ND patients exhibited higher response rates to dabrafenib and trametinib compared with cfDNA V600E/K patients; Supplement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67497579b822a676faffaa50ba0c91b5
https://doi.org/10.1158/1078-0432.22461467.v1
https://doi.org/10.1158/1078-0432.22461467.v1
Autor:
Patricia Haney, Michelle Casey, Keith T. Flaherty, Anne O'Hagan, Ademi Santiago-Walker, Dirk Schadendorf, Vicki L. Goodman, Axel Hauschild, Jeffrey J. Legos, Richard F. Kefford, Robert C. Gagnon, Patrick Hwu, Jolly Mazumdar, Anne-Marie Martin, Georgina V. Long, Jennifer Carver
Publikováno v:
Clinical Cancer Research. 22:567-574
Purpose: Tumor-derived circulating cell–free DNA (cfDNA) is a potential alternative source from which to derive tumor mutation status. cfDNA data from four clinical studies of the BRAF inhibitor (BRAFi) dabrafenib or the MEK inhibitor (MEKi) tramet
Autor:
Vanna Chiarion-Sileni, Michael Millward, J.-J. Grob, Kelly M. Grotzinger, Salvador Martín-Algarra, Boguslawa Karaszewska, Vicki L. Goodman, Lev V. Demidov, Mayur M. Amonkar, Suzanne Swann, Patricia Haney, E. Kämpgen, Wilson H. Miller, Axel Hauschild, Piotr Rutkowski, Cornelia Mauch, Beloo Mirakhur
Publikováno v:
Annals of Oncology. 25:1428-1436
Background: In a randomized phase III study (BREAK-3), dabrafenib showed prolonged progression-free survival (PFS) (median 5.1 versus 2.7 months; hazard ratio = 0.30; 95% confidence interval 0.18–0.53; P < 0.0001) compared with dacarbazine (DTIC) i
Autor:
Anne O'Hagan, Ekaterina Gibiansky, Daniele Ouellet, Julie Switzky, Vicki L. Goodman, Patricia Haney, Cathrine Leonowens
Publikováno v:
The Journal of Clinical Pharmacology. 54:696-706
Dabrafenib is a BRAF kinase inhibitor indicated for the treatment of BRAF V600E mutation-positive melanoma. The population pharmacokinetics of dabrafenib, including changes over time and relevant covariates, were characterized based on results from f
Autor:
Christian U. Blank, Jean-Jacques Grob, Paul B. Chapman, Vicki L. Goodman, Cornelia Mauch, Anne-Marie Martin, Michael Millward, Eckhart Kaempgen, Lev V. Demidov, Wilson H. Miller, Axel Hauschild, Thomas Jouary, Piotr Rutkowski, Salvador Martín-Algarra, Suzanne Swann, Ralf Gutzmer, Patricia Haney, Mary E. Guckert, Beloo Mirakhur, Vanna Chiarion-Sileni, Boguslawa Karaszewska
Publikováno v:
The Lancet. 380:358-365
Summary Background Dabrafenib, an inhibitor of mutated BRAF, has clinical activity with a manageable safety profile in studies of phase 1 and 2 in patients with BRAF V600 -mutated metastatic melanoma. We studied the efficacy of dabrafenib in patients
Autor:
Daniele, Ouellet, Ekaterina, Gibiansky, Cathrine, Leonowens, Anne, O'Hagan, Patricia, Haney, Julie, Switzky, Vicki L, Goodman
Publikováno v:
Journal of clinical pharmacology. 54(6)
Dabrafenib is a BRAF kinase inhibitor indicated for the treatment of BRAF V600E mutation-positive melanoma. The population pharmacokinetics of dabrafenib, including changes over time and relevant covariates, were characterized based on results from f
Autor:
Eric Pujade-Lourraine, Jonathan A. Ledermann, Michael Shnaidman, Mary L. Disis, Alexei Morozov, J. Thaddeus Beck, Patricia Haney, Mansoor Raza Mirza, Stephanie Gaillard, Bradley J. Monk, Nicoletta Colombo, Gary Richardson, Keiichi Fujiwara
Publikováno v:
Journal of Clinical Oncology. 34:TPS5600-TPS5600
TPS5600Background: Programmed death-1 receptor ligand (PD-L1) is a key therapeutic target in the reactivation of the immune response against multiple cancers. Avelumab* is a fully human anti-PD-L1 ...
Autor:
Gursel Aktan, Paul B. Chapman, Christian U. Blank, Boguslawa Karaszewska, Axel Hauschild, V. Chiarion Sileni, Fan Jin, Jeffrey J. Legos, Piotr Rutkowski, Michael Millward, J. Grobb, Lev V. Demidov, Ralf Gutzmer, Salvador Martín-Algarra, Suzanne Swann, Wilson H. Miller, Patricia Haney, Thomas Jouary, Cornelia Mauch
Publikováno v:
Annals of Oncology. 25:iv378
Aim: The primary analysis of BREAK-3 (NCT01227889) comparing progression-free survival in pts with BRAF V600E mutation-positive MM treated with D or DTIC was previously reported (Hauschild A, et al. Lancet 2012; 380:358–65). Median OS of D and DTIC